Clin Case Rep Int | Volume 7, Issue 1 | Case Report | Open Access

Vedolizumab Like Biological First Choice for Chronic Refractory Pouchitis in Patients with Ulcerative Colitis

Vincenzo T^* and Annamaria D

Department of Medical and Surgical Sciences, University “Magna Graecia” of Catanzaro, Italy

^*Correspondance to: Trapanese Vincenzo 

Abstract

Chronic Antibiotic-Refractory Pouchitis (CARP) is a complication of Ileal Pouch-Anal Anastomosis (IPAA), which poses a therapeutic challenge. Vedolizumab, a gut-selective monoclonal antibody to the α4β7 of integrin, has been used in such patients, but data on its efficacy are limited. Our case suggests the efficacy and safety of vedolizumab as induction therapy in CARP patient without a previous experience with anti-TNF agents. Larger studies with a higher number of patients are required to confirm these findings.

Keywords:

Vedolizumab; Chronic antibiotic-refractory puchitits; Ulcerative Colitis

Citation:

Vincenzo T, Annamaria D. Vedolizumab Like Biological First Choice for Chronic Refractory Pouchitis in Patients with Ulcerative Colitis. Clin Case Rep Int. 2023; 7: 1474..